Welcome to our dedicated page for LeMaitre Vascular news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on LeMaitre Vascular stock.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) is a leading provider of medical devices and implants for the treatment of peripheral vascular disease, a condition that affects over 200 million people globally. The company develops, manufactures, and markets disposable and implantable vascular devices aimed at addressing the needs of vascular surgeons. LeMaitre Vascular offers a diversified product portfolio that includes angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems.
Headquartered in Burlington, Massachusetts, LeMaitre's products are utilized during open vascular surgeries, primarily focusing on several anatomical areas such as the carotid, lower extremities, upper extremities, and aorta. The company's lower extremities product line generates the highest revenue, followed by the carotid product line. In recent financial updates, the company reported significant growth in sales across various product categories including bovine patches, valvulotomes, and carotid shunts.
LeMaitre Vascular continues to demonstrate robust financial health. For Q3 2023, the company reported a 21% increase in sales and a 49% rise in operating income, driven by price increases and operational efficiencies. Operating income for Q4 2023 was up 46%, reflecting strong sales growth and improved gross margins. In addition, LeMaitre has a share repurchase program and regularly pays dividends to its shareholders, exemplifying its commitment to shareholder value.
Furthermore, LeMaitre Vascular is focused on expanding its global footprint. Sales in the Americas, EMEA, and APAC regions have shown substantial growth, contributing significantly to the company's revenue. The company also emphasizes compliance with global regulatory requirements, ensuring that its products meet stringent quality standards.
LeMaitre frequently engages with investors through earnings calls, providing transparency about its financial performance and strategic outlook. The company remains committed to innovation and development, constantly working on new projects to enhance its product offerings and address emerging market needs.
For more information about LeMaitre Vascular and its latest updates, visit their official website at www.lemaitre.com.
LeMaitre (Nasdaq:LMAT) reported Q3 2021 sales of $38.4 million, a 5% increase year-over-year, with a gross margin of 64.8%, up 250 basis points. Operating income dropped 9% to $9.1 million, and net income fell 13% to $6.5 million. Earnings per diluted share were $0.30, down 19%. The company announced a quarterly dividend of $0.11 per share. Guidance for Q4 2021 expects sales between $39.0 million and $41.0 million, with a gross margin of 66.3%. CEO George LeMaitre noted challenges from the Delta variant affecting elective surgeries.
LeMaitre Vascular, Inc. (LMAT) will announce its Q3 2021 financial results on October 28, 2021, following the market's close. A conference call is scheduled for 5:00 PM ET that same day to discuss the results and company outlook. The call can be accessed by dialing 844-239-5284 (international: +1-512-961-6497) and is available via a webcast at www.lemaitre.com/investor. LeMaitre provides vascular devices for treating peripheral vascular disease, serving a global market of over 200 million individuals.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in four virtual investor conferences throughout September 2021. Key events include the Barrington Research 14th Annual Virtual Fall Investment Conference and Morgan Stanley's 19th Annual Global Healthcare Conference, both on September 9. Additionally, LeMaitre will participate in Lake Street's 5th Annual Best Ideas Growth Conference on September 14 and the 2021 Cantor Virtual Global Healthcare Conference on September 27, where David Roberts, President, will present at 8:00 AM ET.
LeMaitre specializes in devices and services for peripheral vascular disease, impacting over 200 million globally.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two investor conferences in August 2021. CFO JJ Pellegrino will present at the Canaccord Genuity 41st Annual Growth Conference on August 12 at 9:00 AM EDT and will also attend the Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16. LeMaitre specializes in devices and services for treating peripheral vascular disease, which impacts over 200 million people globally.
LeMaitre (Nasdaq:LMAT) reported Q2 2021 results with sales of $40.7 million, a 64% increase year-over-year. Operating income rose by 128% to $11.1 million, yielding an operating margin of 27%. Net income jumped 137% to $8.3 million, with earnings per diluted share at $0.40, a 131% increase. Despite a gross margin decline to 65.8%, driven by product mix and manufacturing inefficiencies, the company completed a $54.5 million follow-on stock offering. Q3 2021 guidance suggests sales between $38.3 million and $40.3 million.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will announce its Q2 2021 financial results on July 29, 2021, after market close. A conference call is set for the same day at 5:00 PM ET to discuss the results and company outlook. The call can be accessed by dialing 844-239-5284 or through a webcast at the company’s investor relations page. LeMaitre specializes in devices for peripheral vascular disease, serving over 200 million worldwide.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) has priced a public offering of 1,000,000 shares at $54.50 each, expecting gross proceeds of approximately $54.5 million. Closing is anticipated around July 16, 2021. Underwriters have an option to buy 150,000 additional shares. Proceeds will be used to repay senior secured credit facility borrowings, for corporate purposes, and potential acquisitions. The offering follows SEC registration and is conducted via a prospectus. Jefferies and Stifel are the joint book-running managers for this offering.
LeMaitre Vascular (Nasdaq:LMAT) has begun an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The proceeds will be used to fully repay borrowings under its senior secured credit facility and for corporate purposes, including working capital and potential acquisitions. Jefferies LLC and Stifel are the joint book-running managers. The offering is subject to market conditions, and details will be available in the SEC filings.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced preliminary Q2 2021 results, reporting net sales of $40.7 million, a 64% increase compared to Q2 2020, with organic growth of 35%. Operating income reached approximately $10.9 million to $11.3 million, up 128%. The gross margin declined to 65.5%-66.1%, impacted by inventory write-downs and manufacturing inefficiencies. Geographic sales growth was strong across all regions, especially in the Americas (+83%). Cash and cash equivalents stood at $21.8 million, while debt decreased by $9 million to $23 million.
LeMaitre Vascular (Nasdaq:LMAT) announced that President David Roberts will present at the Goldman Sachs 42nd Annual Virtual Global Healthcare Conference on June 10, 2021, at 5:30 PM ET. The company specializes in devices, implants, and services for peripheral vascular disease, affecting over 200 million people globally. LeMaitre develops and markets vascular devices tailored to vascular surgeons.
FAQ
What is the current stock price of LeMaitre Vascular (LMAT)?
What is the market cap of LeMaitre Vascular (LMAT)?
What products does LeMaitre Vascular offer?
Where is LeMaitre Vascular headquartered?
In which medical areas are LeMaitre's products primarily used?
What was the company's financial performance in Q3 2023?
How does LeMaitre Vascular engage with its investors?
What regions contribute significantly to LeMaitre's revenue?
Does LeMaitre Vascular pay dividends to its shareholders?
What recent financial achievements has LeMaitre Vascular reported?
How does LeMaitre ensure the quality of its products?
Where can I find more information about LeMaitre Vascular?
